scholarly journals Anemia, chronic renal disease and chronic heart failure: the cardiorenal anemia syndrome

2008 ◽  
Vol 10 (4) ◽  
pp. 189-196 ◽  
Author(s):  
DONALD S. SILVERBERG ◽  
DOV WEXLER ◽  
ADRIAN IAINA ◽  
DORON SCHWARTZ
Author(s):  
Hui-Hsuan Lai ◽  
Pei-Ying Tseng ◽  
Chen-Yu Wang ◽  
Jong-Yi Wang

Few large-scale studies have focused on tracheostomy in patients with prolonged mechanical ventilation. This retrospective population-based study extracted data from the longitudinal National Health Insurance Research Database in Taiwan to compare long-term mortality between patients on prolonged mechanical ventilation with and without tracheostomy and their related medical expenditures. Data on newly developed respiratory failure in patients on ventilator support were extracted from 1 January 2002 to 31 December 2008. Of 10,705 patients included, 1372 underwent tracheostomy (n = 563) or translaryngeal intubation (n = 779). Overall survival of the patients with tracheostomy was followed for 5 years. Average survival was 4.98 years for the patients with tracheostomy and 5.48 years for the patients with translaryngeal intubation (not significant). Sex, age, premium-based monthly salary difference, occupation, urbanization level, chronic obstructive pulmonary disease, chronic heart failure, chronic renal disease, and cerebrovascular diseases were significantly associated with mortality for endotracheal intubation. Male sex, chronic heart failure, chronic renal disease, age ≥45 years, and low income were associated with significantly higher mortality. Although total medical expenditures were higher for the patients with tracheostomy, annual medical expenditures were not significantly different. There were no differences in long-term mortality between the two groups.


2001 ◽  
Vol 21 (1) ◽  
pp. 3-12 ◽  
Author(s):  
Amin Al-Ahmad ◽  
Mark J. Sarnak ◽  
Deeb N. Salem ◽  
Marvin A. Konstam

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 517-517
Author(s):  
Eric J Chow ◽  
K. Scott Baker ◽  
Debra L. Friedman ◽  
Kara Cushing-Haugen ◽  
Mary E.D. Flowers ◽  
...  

Abstract Abstract 517 BACKGROUND: There is growing evidence that recipients of hematopoietic cell transplantation (HCT) have increased risk of adverse long-term effects such as hypertension, dyslipidemia, and diabetes which may contribute to increased cardiovascular (CV) morbidity and mortality. METHODS: The Fred Hutchinson Cancer Research Center (FHCRC) performs the vast majority of HCTs in Washington State. We linked the medical records of all 2-year HCT survivors who were state residents treated at FHCRC from 1985-2005 (n=1405; 62% allogeneic; 38% autologous) to the state's hospital discharge and death registries beginning 2 years after HCT. Individuals randomly selected from state driver's license files (n=5964) served as a comparison group, frequency-matched by age, sex, and county of residence. Selected serious CV diagnoses (ischemic heart disease, dysrhythmia, cardiomyopathy/heart failure, stroke and other vascular disease) and related diseases (dyslipidemia, diabetes, chronic renal disease) were identified from these databases for the HCT and comparison cohorts. Odds ratio (OR) estimates of the relative risk were calculated using logistic regression adjusted for age and year of HCT/driver's license filing, sex, and race/ethnicity (HCT patients only). RESULTS: With a median age at HCT of 40 (0-73) years and follow-up time of 5 (2-22) years since HCT, survivors were significantly more likely to have subsequent CV and related diagnoses recorded in hospital discharge (28% vs. 10%; p<0.01) and death records (4% vs. 1%; p<0.01) vs. the comparison group. In particular, dysrhythmia, cardiomyopathy/heart failure, stroke and other vascular diseases, diabetes, and chronic renal disease were recorded more frequently among the HCT cohort. Rates of ischemic heart disease were not significantly different between the 2 groups (4% vs. 3%; p=0.14). In multivariable analyses, factors independently associated with increased CV hospitalizations included history of chronic graft vs. host disease (OR 2.0 [1.4-2.7]) and receiving >1 HCT of any type (OR 2.1 [1.4-3.0]). Receiving >1 HCT also was associated with statistically significant 2-3 fold increased risks of dysrhythmia, cardiomyopathy/heart failure, and chronic renal disease. Allogeneic transplants and preparative regimens containing total body irradiation (TBI) were not associated with an increased risk of CV hospitalization compared with autologous transplants and non-TBI containing regimens, respectively. While older age at baseline was associated with an increased risk of most CV outcomes in both groups, in age-stratified analysis, those who received HCT at a younger age had the greatest risk vs. similar-aged comparison subjects (e.g. <20 years at HCT, CV hospitalization OR=37.8 [16.5-86.2]; ≥60 years at HCT, OR=1.7 [1.1-2.6]). In contrast to the comparison group, among HCT survivors increased body mass index was not consistently associated with an increased risk of CV outcomes except for diabetes. CONCLUSIONS: CV-related hospitalizations and deaths occurred significantly more often among 2-year HCT survivors than the comparison group, as measured by hospital discharge and death registries. Similar risk was observed following allogeneic and autologous transplants. Patients who received HCT at a younger age and those who experienced multiple transplants of any type were at particularly increased risk. To more completely delineate risk factors, future analyses will examine the effects of pre-HCT anthracycline and chest radiotherapy exposures, and elapsed time since HCT. Disclosures: No relevant conflicts of interest to declare.


2021 ◽  
Vol 23 (Supplement_G) ◽  
Author(s):  
Luca Licchelli ◽  
Laura De Michieli ◽  
Giulio Sinigiani ◽  
Tamara Berno ◽  
Lorenzo Previato ◽  
...  

Abstract Aims Despite improved awareness and advances in cardiac imaging, cardiac amyloidosis (CA) is a substantially underdiagnosed disease. ATTRwt amyloidosis may be responsible for as many as 30% of HF with preserved ejection fraction in patients &gt;75 years old. Contemporary estimates of its epidemiology in Italy are poorly provided. The aim of this study is to retrospectively analyse yearly inpatient claims consistent with amyloidosis in a single centre of Veneto region (Azienda Ospedaliera—Università di Padova). Methods Inpatient claims were counted in the series in each year if they had at least 1 principal or secondary International Classification of Diseases, Ninth revision—clinical modification (ICD-9, CM) code for amyloidosis (27730-27739), from January 2009 to February 2021. Primary outcome was to clarify if an increase in claims went hand in hand with novel and wider awareness of the disease. Secondary outcome was to identify major comorbidities determining or accompanying acute conditions leading to hospitalization. Results During the study period, there was a total of 328 claims containing ICD9-CM code for amyloidosis; 139 of them (42%) registered before 2015, 189 (58%) after 2015. Mean number of hospitalizations increased during time, starting from 20 claims per year between 2009 and 2015, to 36.8 from 2015 to 2020 (excluded current year). Considering main discharge diagnosis, 84 (25.6%) was related to cardiological condition, of them 56 (66%) was about acute or acute on chronic heart failure, 9 (10.7%) to arrhythmias, both brady- and tachyarrhythmia, 6 (7.1%) to coronary disease, 4 (4.8%) to aortic stenosis. The other most frequent discharge diagnoses, 36 (10.9%) were due to neurological condition, mostly neurovascular disease, 26 (7.9%) were due to haematological disease, mostly multiple myeloma, 14 (4.2%) were about nephrological condition, mostly related to advanced or pre-dialysis renal disease. Regarding related discharge diagnoses, the most frequent were cardiological conditions, appearing in 205 (62.5%) claims. 128 (62.4%) of them were due to acute or chronic heart failure, 10 (4.1%) to brady-tachyarrhythmias, 9 (4.4%) to ischaemic heart disease, and 6 (2.9%) to aortic valve disease. About other associated conditions reported in ICD9-CM codes used 84 (25.6%) were related to haematological diseases, 68 (20.7%) to neurological disease, 52 (15.8%) to renal disease, 23 (7%) to gastroenterological diagnoses (mostly GI bleeding). Conclusions Over the last years, there have been a substantial increase in amyloidosis diagnosis in our centre. This appears to go hand in hand with an increase in clinicians’ CA awareness, as confirmed by the fact that main discharge diagnosis is related to cardiac condition, and more specifically heart failure. Heart is again the most important comorbidity in patients hospitalized for other conditions, mostly related to nephrological, neurological, haematological affections confirming its role as main prognostic determinant in a complex disease, and the necessity to search for it, find it and quickly cure it.


2004 ◽  
Vol 13 (2) ◽  
pp. 163-170 ◽  
Author(s):  
Donald Silverberg ◽  
Dov Wexler ◽  
Miriam Blum ◽  
Doron Schwartz ◽  
Adrian Iaina

Sign in / Sign up

Export Citation Format

Share Document